Prevention and treatment of androgen-deprivation induced osteoporosis

A method of preventing androgen-deprivation induced osteoporosis in a male subject suffering from prostate cancer, said method comprising the step of administering to said subject an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, in an amount effective to prevent androgen-deprivation induced osteoporosis in said subject.

A method of suppressing or inhibiting androgen-deprivation induced osteoporosis in a male subject suffering from prostate cancer, said method comprising the step of administering to said subject an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, in an amount effective to suppress or inhibit androgen-deprivation induced osteoporosis in said subject.

A method of reducing the risk of developing androgen-deprivation induced osteoporosis in a male subject suffering from prostate cancer, said method comprising the step of administering to said subject an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, in an amount effective to reduce the risk of developing androgen-deprivation induced osteoporosis in said subject.

A method of treating androgen-deprivation induced loss of bone mineral density (BMD) in a male subject suffering from prostate cancer, said method comprising the step of administering to said subject an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, in an amount effective to treat androgen-deprivation induced bone loss in said subject.

A method of preventing androgen-deprivation induced loss of bone mineral density (BMD) in a male subject suffering from prostate cancer, said method comprising the step of administering to said subject an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, in an amount effective to prevent androgen-deprivation induced bone loss in said subject.

A method of suppressing or inhibiting androgen deprivation-induced loss of bone mineral density (BMD) in a male subject suffering from prostate cancer, said method comprising the step of administering to said subject an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, in an amount effective to suppress or inhibit androgen-deprivation induced bone loss in said subject.

A method of reducing the risk of developing androgen deprivation-induced loss of bone mineral density (BMD) in a male subject suffering from prostate cancer, said method comprising the step of administering to said subject an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, in an amount effective to reduce the risk of developing androgen-deprivation induced bone loss in said subject.

A method of treating androgen-deprivation induced bone fractures in a male subject suffering from prostate cancer, said method comprising the step of administering to said subject an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, in an amount effective to treat androgen-deprivation induced bone loss in said subject, in an amount effective to treat androgen-deprivation induced bone fractures in said subject.

A method of preventing androgen-deprivation induced bone fractures in a male subject suffering from prostate cancer, said method comprising the step of administering to said subject an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, in an amount effective to prevent androgen-deprivation induced bone fractures in said subject.

A method of suppressing or inhibiting androgen-deprivation induced bone fractures in a male subject suffering from prostate cancer, said method comprising the step of administering to said subject an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, in an amount effective to suppress or inhibit androgen-deprivation induced bone fractures in said subject.

A method of reducing the risk of developing androgen-deprivation induced bone fractures in a male subject suffering from prostate cancer, said method comprising the step of administering to said subject an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, in an amount effective to reduce the risk of developing androgen-deprivation induced bone fractures in said subject.